Format

Send to

Choose Destination
Stem Cell Res Ther. 2015 Mar 14;6:29. doi: 10.1186/s13287-015-0020-6.

Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial).

Author information

1
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. rubenssiqueira@terra.com.br.
2
Rubens Siqueira Research Center, Sao Jose do Rio Preto, SP, Brazil. rubenssiqueira@terra.com.br.
3
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Avenida Bandeirantes, 3900, Ribeirao Preto, SP, 14049-900, Brazil. rubenssiqueira@terra.com.br.
4
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. amessias@hotmail.com.
5
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. Katharina.Messias@gmail.com.
6
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. rsarc@bol.com.br.
7
Department of Bone Marrow Transplantation, Beneficencia Portuguesa Hospital, Sao Jose do Rio Preto, SP, Brazil. milruiz@yahoo.com.br.
8
Rubens Siqueira Research Center, Sao Jose do Rio Preto, SP, Brazil. Neiglene@hotmail.com.
9
Discipline of Biology, Paulista University (UNIP), Sao Jose do Rio Preto, SP, Brazil. liacampanha1@gmail.com.
10
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. retinausp@hotmail.com.

Abstract

INTRODUCTION:

Retinitis pigmentosa (RP) is a severe neurodegenerative disease of the retina that can lead to blindness. Even without treatment, a clinical study with the use of stem cells is currently underway and the results are being evaluated. In the present report we assess the vision-related quality of life in patients with RP submitted to intravitreal use of bone marrow-derived stem cells.

METHOD:

The study included 20 patients with RP submitted to intravitreal use of bone marrow-derived stem cells. We evaluate the vision-related quality of life (VRQOL) of patients using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). Patients were scheduled to answer the questionnaire before treatment and 3 and 12 months after treatment.

RESULTS:

All patients completed the survey as scheduled. There was a statistically significant improvement (P<0.05) in the quality of life of patients 3 months after treatment, whereas by the 12th month there was no statistically significant difference from baseline.

CONCLUSIONS:

Cell therapy with intravitreal use of bone marrow-derived stem cells can improve the quality of life of patients with RP, although the improvement is lost with time. A larger number of cases will be necessary to evaluate the repercussions of this therapy on the quality of life of these patients.

TRIAL REGISTRATION:

Clinicaltrials.gov: NCT01560715 . Registered March 19, 2012.

PMID:
25890251
PMCID:
PMC4393588
DOI:
10.1186/s13287-015-0020-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center